Cohance Lifesciences Limited Latest Updates

US FDA Inspection Completed with Four Observations at Shamshabad Facility On September 5, 2026, the company informed stock exchanges under Regulation 30 disclosures that the US FDA concluded an inspection at its formulation (Finished Dosage Form - FDF) manufacturing facility located in Shamshabad, Telangana. The inspection, carried out up to September 4, 2026, closed with the issuance of Form FDA 483 containing four inspectional observations. The company stated that none of the observations pertain to data integrity and confirmed that it is actively preparing a comprehensive response with corrective and preventive action (CAPA) plans within the prescribed timeline. Q1 FY27 Financial Results & Bottom-Line Contraction In August 2026, Cohance Lifesciences reported its consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). Consolidated total income stood at ₹434.51 crore, contracting from ₹563.48 crore in Q1 FY26, impacted by timing of customer batches and inventory rationalization across CDMO innovator accounts. The company posted a consolidated net loss (PAT) of ₹24.12 crore (compared to a profit after tax of ₹48.88 crore in the corresponding prior-year period), leading to an operational margin compression during the quarter. Key Leadership Changes & Executive Transition Under senior management governance disclosures, Chief Financial Officer (CFO) Himanshu Agarwal tendered his resignation to pursue external opportunities, with his formal relief from executive responsibilities effective September 13, 2026. The Board initiated the succession and appointment process to transition the finance leadership portfolio smoothly ahead of upcoming capital planning milestones.